Release Date: 2024-06-12

Immunotherapy in Solid Tumors

Ziya Kalkan (Author), Zeynep Oruc (Author)

Release Date: 2024-06-12

Immunotherapy addresses the immune suppression originating from the tumor and its microenvironment, so that the immune system targets and kills cancer cells. Surgical resection has the potential to offer a cure in some cases, but the majority of advanced solid tumors are not suitable for using this method. Long-lasting and durable responses are achieved with [...]

Media Type
    Buy from

    Price may vary by retailers

    Work TypeBook Chapter
    Published inImmunotherapy in Human Cancers
    First Page141
    Last Page149
    DOIhttps://doi.org/10.69860/nobel.9786053359388.10
    Page Count9
    Copyright HolderNobel Tıp Kitabevleri
    Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

    Immunotherapy addresses the immune suppression originating from the tumor and its microenvironment, so that the immune system targets and kills cancer cells. Surgical resection has the potential to offer a cure in some cases, but the majority of advanced solid tumors are not suitable for using this method. Long-lasting and durable responses are achieved with immunotherapy in some patient groups. Cancer immunotherapy is incorporated into multidisciplinary cancer treatment gradually more, partly thanks to its potential to provide permanent disease control for more patients. Further studies are needed to expand the impact of immunotherapy to include a broader range of solid tumor types.

    Ziya Kalkan (Author)
    MD, Specialist of Medical Oncology, Mardin Government Hospital
    https://orcid.org/0000-0001-7858-8180
    3Medical Oncology, MD. Ziya KALKAN Education. Dicle university medicine faculty (2003-2009) Internal Medicine specilization. Dicle university Medicine faculty (2013-2017) Medical Oncology, Departrment of Medical Oncology. Dicle university (2019-2023) Medical Oncology,Doçent

    Zeynep Oruc (Author)
    MD, Assoc. Prof., Dicle University
    https://orcid.org/0000-0002-7931-2941
    3Dr.Zeynep Oruç Education: Lisans,anadal; İnönü Üniversitesi Tıp Fakültesi 2000-2007 Tıpta uzmanlık,anadal; Ankara Üniversitesi Tıp Fakültesi,İç hastalıkları Anabilim dalı 2007-2012 Dahiliye uzmanı; Diyarbakır Eğitim ve Araştırma Hastanesi,İç hastalıkları 2012-2013 Lisans,yan dal, Dicle Üniversitesi Tıp Fakültesi,Tıbbi Onkoloji Bilim Dalı 2013-2017 Tibbi Onkoloji Uzmanı; Mersin Şehir Hastanesi,Tibbi Onkoloji Ünitesi 2017-2019 Dr.öğretim üyesi;Dicle Üniversitesi Tıp Fakültesi,Tibbi Onkoloji Bilim Dalı,11.2019-01.2022 Doç.Dr; Dicle Üniversitesi Tıp Fakültesi,Tibbi Onkoloji Bilim Dalı,01.2022-halen

    • Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci 1893; 105:487.

    • Harding, F.A.; McArthur, J.G.; Gross, J.A.; Raulet, D.H.; Allison, J.P. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992, 356, 607–609.

    • Tivol, E.A.; Borriello, F.; Schweitzer, A.N.; Lynch, W.P.; Bluestone, J.A.; Sharpe, A.H. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995, 3, 541–547.

    • Keir, M.E.; Butte, M.J.; Freeman, G.J.; Sharpe, A.H. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008, 26, 677–704.

    • Garon, E.B.; Rizvi, N.A.; Hui, R.; Leighl, N.; Balmanoukian, A.S.; Eder, J.P.; Patnaik, A.; Aggarwal, C.; Gubens, M.; Horn, L.; et al. Pembrolizumab for the treatment of non-smallcell lung cancer. N Engl J Med. 2015, 372, 2018–2028.

    • De Angelis, C. Side Effects Related to Systemic Cancer Treatment: Are We Changing the Promethean Experience with Molecularly Targeted Therapies? Curr Oncol. 2008, 15, 198– 199.

    • Baskar, R.; Lee, K.A.; Yeo, R.; Yeoh, K.-W. Cancer and Radiation Therapy: Current Advances and Future Directions. Int J Med. Sci. 2012, 9, 193–199.

    • Motzer RJ, McDermott DF, Escudier B, et al. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer 2022; 128:2085.

    • Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2015; 26:2375.

    • Champiat, S.; Lambotte, O.; Barreau, E.; Belkhir, R.; Berdelou, A.; Carbonnel, F.; Cauquil, C.; Chanson, P.; Collins, M.; Durrbach, A.; et al. Management of immune checkpoint blockade dysimmune toxicities: A collaborative position paper. Ann Oncol. 2016, 27, 559– 574.

    • Mellman, I.; Coukos, G.; Dranoff, G. Cancer immunotherapy comes of age. Nature 2011, 480, 480–489.

    • Pento, J.T. Monoclonal Antibodies for the Treatment of Cancer. Anticancer Res. 2017, 37, 5935–5939.

    • Lipson, E.J.; Drake, C.G. Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma. Clin. Cancer Res. 2011, 17, 6958–6962.

    • Robert, C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020, 11, 3801.

    • Rotte, A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res. 2019, 38, 255.

    • Hodi, F.S.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J.-J.; Rutkowski, P.; Cowey, C.L.; Lao, C.D.; Schadendorf, D.; Wagstaff, J.; Dummer, R.; et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018, 19, 1480–1492.

    • Johnson, D.B.; Chandra, S.; Sosman, J.A. Immune Checkpoint Inhibitor Toxicity in 2018. JAMA 2018, 320, 1702–1703.

    • Duffy, M.J.; Crown, J. Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients. Clin. Chem. 2019, 65, 1228–1238.

    • Torisu-Itakura, H.; Schoellhammer, H.F.; Sim, M.-S.; Irie, R.F.; Hausmann, S.; Raum, T.; Baeuerle, P.A.; Morton, D.L. Redirected Lysis of Human Melanoma Cells by a MCSP/ CD3-bispecific BiTE Antibody That Engages Patient-derived T Cells. J Immunother. 2011, 34, 597–605.

    • Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017 Mar 2;376(9):836-847.

    • Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022 Aug 11;387(6):495-505.

    • de Gruijl TD, Janssen AB, van Beusechem VW. Arming oncolytic viruses to leverage antitumor immunity. Expert Opin Biol Ther 2015; 15:959.

    • Bommareddy, P.K.; Patel, A.; Hossain, S.; Kaufman, H.L. Talimogene Laherparepvec (T VEC) and Other Oncolytic Viruses for the Treatment of Melanoma. Am. J. Clin. Dermatol. 2016, 18, 1–15.

    • Jou, J.; Harrington, K.J.; Zocca, M.-B.; Ehrnrooth, E.; Cohen, E.E. The Changing Landscape of Therapeutic Cancer Vaccines—Novel Platforms and Neoantigen Identification. Clin. Cancer Res. 2020, 27, 689–703.

    • Lollini, P.L.; Cavallo, F.; Nanni, P.; Forni, G. Vaccines for tumour prevention. Nat. Cancer 2006, 6, 204–216. i. Chapter 10 IMMUNOTHERAPY IN SOLID TUMORS 149

    • Lamm, D.L.; Blumenstein, B.A.; Crawford, E.D.; Montie, J.E.; Scardino, P.; Grossman, H.B.; Stanisic, T.H.; Smith, J.A.; Sullivan, J.; Sarosdy, M.F.; et al. A Randomized Trial of Intravesical Doxorubicin and Immunotherapy with Bacille Calmette–Guérin for Transitional-Cell Carcinoma of the Bladder. N. Engl. J. Med. 1991, 325, 1205–1209.

    • DeMaria, P.J.; Bilusic, M. Cancer Vaccines. Hematol. Oncol. Clin. N. Am. 2019, 33, 199– 214.

    • Laheru, D.; Lutz, E.; Burke, J.; Biedrzycki, B.; Solt, S.; Onners, B.; Tartakovsky, I.; Nemunaitis, J.; Le, D.; Sugar, E.; et al. Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation. Clin. Cancer Res. 2008, 14, 1455–1463.

    • Lipson, E.J.; Sharfman, W.H.; Chen, S.; McMiller, T.L.; Pritchard, T.S.; Salas, J.T.; Sartorius-Mergenthaler, S.; Freed, I.; Ravi, S.; Wang, H.; et al. Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting. J. Transl. Med. 2015, 13, 214.

    • Salgia, R.; Lynch, T.; Skarin, A.; Lucca, J.; Lynch, C.; Jung, K.; Hodi, F.S.; Jaklitsch, M.; Mentzer, S.; Swanson, S.; et al. Vaccination With Irradiated Autologous Tumor Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor Augments Antitumor Immunity in Some Patients With Metastatic Non Small-Cell Lung Carcinoma. J. Clin. Oncol. 2003, 21, 624–630.

    • Small, E.J.; Sacks, N.; Nemunaitis, J.; Urba,W.J.; Dula, E.; Centeno, A.S.; Nelson,W.G.; Ando, D.; Howard, C.; Borellini, F.; et al. Granulocyte Macrophage Colony-Stimulating Factor–Secreting Allogeneic Cellular Immunotherapy for Hormone-Refractory Prostate Cancer. Clin. Cancer Res. 2007, 13, 3883–3891.

    • Rosenberg, S.A.; Restifo, N.P.; Yang, J.C.; Morgan, R.A.; Dudley, M.E. Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat. Cancer 2008, 8, 299–308.

    • Besser, M.J.; Shapira-Frommer, R.; Itzhaki, O.; Treves, A.J.; Zippel, D.B.; Levy, D.; Kubi, A.; Shoshani, N.; Zikich, D.; Ohayon, Y.; et al. Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies. Clin. Cancer Res. 2013, 19, 4792–4800.

    • Porter, D.L.; Levine, B.L.; Kalos, M.; Bagg, A.; June, C.H. Chimeric Antigen Receptor– Modified T Cells in Chronic Lymphoid Leukemia. N. Engl. J. Med. 2011, 365, 725–733.

    • Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994; 271:907.

    • Kokoscka EM, Trautinger, Knobler RM: Long term adjuvant therapy of high-risk malignant melanoma with interferon alfa -2b. J Invest Dermatol. 1990; 95: S 193–7.

    • Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer--a current perspective. Nat Rev Urol 2014; 11:153.

    onix_3.0::thothThoth ONIX 3.0
    onix_3.0::project_museProject MUSE ONIX 3.0
    onix_3.0::oapenOAPEN ONIX 3.0
    onix_3.0::jstorJSTOR ONIX 3.0
    onix_3.0::google_booksGoogle Books ONIX 3.0
    onix_3.0::overdriveOverDrive ONIX 3.0
    onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
    csv::thothThoth CSV
    json::thothThoth JSON
    kbart::oclcOCLC KBART
    bibtex::thothThoth BibTeX
    doideposit::crossrefCrossRef DOI deposit
    onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
    marc21record::thothThoth MARC 21 Record
    marc21markup::thothThoth MARC 21 Markup
    marc21xml::thothThoth MARC 21 XML

    Share This Chapter!